Summary

The cell culture market is projected to reach USD 58.42 billion by 2031 from an estimated USD 33.07 billion in 2026, at a CAGR of 12.1% during the forecast period of 2026 to 2031. The growth of this market can be attributed to increasing investment and funding for research in cell biology. The rising incidence of chronic diseases such as cancer is boosting the demand for advanced therapies such as tissue engineering and regenerative medicine. This trend is expected to drive the growth of the cell culture market in the coming years.

By application, the biopharmaceutical production segment accounted for the largest share of the market in 2025.
In 2025, the biopharmaceutical production segment accounted for the largest share of the application segment in the global cell culture market. The biopharmaceutical production segment is further categorized into vaccine production, monoclonal antibody production, and other therapeutic protein production. The growing prevalence of infectious diseases is boosting demand for biopharmaceuticals such as vaccines, monoclonal antibodies, and therapeutic proteins, thereby promoting the growth of biopharmaceutical production in the cell culture market.

The sera, media, and reagents segment accounted for a major share of the consumables market in 2025.
The cell culture consumables market is categorized by type into sera, media, and reagents; vessels; and accessories. The sera, media, and reagents segment accounted for the largest share of the cell culture consumables market in 2025. The large share of this segment is attributed to repeated bulk purchases and the need for consumables in the biotechnology and pharmaceutical industries. Research labs and production facilities often require large quantities of sera, media, reagents, vessels, and accessories to sustain continuous cell culture activities. This leads to frequent and substantial procurement for experimentation, testing, and manufacturing processes.

The Asia Pacific region is expected to experience the highest CAGR in the cell culture market from 2026 to 2031.
The cell culture market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding biologics and biosimilar manufacturing, rising vaccine production, increasing cell & gene therapy activity, and growing government support for domestic biomanufacturing. Countries such as China, India, Japan, South Korea, and Australia are strengthening their cell culture capabilities through investments in biopharmaceutical production, regenerative medicine, stem cell research, and advanced bioprocessing infrastructure. The region is also benefiting from growing CDMO activity, cost-efficient manufacturing, rising clinical research, and wider adoption of serum-free media, single-use systems, culture vessels, reagents, and other cell culture consumables.

The primary interviews conducted for this report can be categorized as follows:

・ By Respondent: Supply Side (70%) and Demand Side (30%)
・ By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
・ By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Plant Cell Technology Inc. (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US) are some of the key companies offering cell culture solutions.

Research Coverage
This research report categorizes the cell culture market by product [consumables (sera, media, reagents; vessels, and other consumables & accessories), equipment (supporting equipment, bioreactors, and storage equipment)], application [biopharmaceutical production (monoclonal antibody production, vaccine production, and other therapeutic protein production), diagnostics, tissue engineering & regenerative medicine (cell & gene therapy and other tissue engineering & regenerative medicine applications), drug screening & development, and other applications], end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the cell culture market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the cell culture market.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the cell culture market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies
The report provides insights on the following pointers:
・ Analysis of key drivers (increasing support and funding for cell-based research, rising demand for serum-free and animal component-free media, growing popularity of monoclonal antibodies and biosimilars, increasing adoption of single-use technologies, and growth in advanced therapy medicinal products), restraints (high cost of cell biology research and limitations in producing high-density cell cultures), opportunities (growing opportunities in emerging economies, rising demand for 3D cell culture, and Increasing focus on next-generation therapeutics), and challenges (ethical concern regarding cell usage, and disposal of plastic consumables) influencing the growth of the market.
・ Product Development/Innovation: Detailed insights on newly launched products of the cell culture market
・ Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell culture market
・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Caisson Labs (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US).
The report also helps stakeholders understand trends in the cell culture market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the cell culture sector.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.2.1 INCLUSIONS & EXCLUSIONS 61
1.3 STUDY SCOPE 61
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 62
1.3.2 YEARS CONSIDERED 63
1.3.3 CURRENCY CONSIDERED 64
1.3.4 UNIT CONSIDERED 64
1.4 STAKEHOLDERS 64
1.5 SUMMARY OF CHANGES 64
2 EXECUTIVE SUMMARY 66
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 66
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 68
2.3 DISRUPTIVE TRENDS IN CELL CULTURE MARKET 69
2.4 HIGH-GROWTH SEGMENTS 70
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 71
3 PREMIUM INSIGHTS 72
3.1 CELL CULTURE MARKET OVERVIEW 72
3.2 NORTH AMERICA: CELL CULTURE MARKET, BY CONSUMABLE AND COUNTRY 73
3.3 CELL CULTURE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
3.4 CELL CULTURE MARKET SHARE, BY END USER 74
4 MARKET OVERVIEW 75
4.1 INTRODUCTION 75
4.2 MARKET DYNAMICS 75
4.2.1 DRIVERS 76
4.2.1.1 Increasing support and funding for cell-based research 76
4.2.1.2 Rising demand for serum-free and animal component-free media 78
4.2.1.3 Growing popularity of monoclonal antibodies and biosimilars 79
4.2.1.4 Increasing adoption of single-use technologies 82
4.2.1.5 Growth in advanced therapy medicinal products 82
4.2.2 RESTRAINTS 84
4.2.2.1 High cost of cell biology research 84
4.2.2.2 Limitations in producing high-density cell cultures 84
 
4.2.3 OPPORTUNITIES 85
4.2.3.1 Rising demand for 3D cell culture 85
4.2.3.2 Growth opportunities in emerging economies 86
4.2.3.3 Increasing focus on next-generation therapeutics 87
4.2.4 CHALLENGES 88
4.2.4.1 Disposal of plastic consumables 88
4.2.4.2 Ethical concerns related to cell usage 89
4.3 UNMET NEEDS & WHITE SPACES 90
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 90
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 91
5 INDUSTRY TRENDS 92
5.1 PORTER’S FIVE FORCES ANALYSIS 92
5.1.1 BARGAINING POWER OF SUPPLIERS 93
5.1.2 BARGAINING POWER OF BUYERS 93
5.1.3 THREAT OF NEW ENTRANTS 93
5.1.4 THREAT OF SUBSTITUTES 93
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.2 MACROECONOMIC OUTLOOK 93
5.2.1 INTRODUCTION 93
5.2.2 GDP TRENDS & FORECAST 94
5.2.3 TRENDS IN GLOBAL CELL CULTURE INDUSTRY 94
5.3 VALUE CHAIN ANALYSIS 95
5.4 ECOSYSTEM ANALYSIS 96
5.5 PRICING ANALYSIS 99
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 99
5.5.2 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS, BY REGION 101
5.6 TRADE ANALYSIS 102
5.6.1 IMPORT SCENARIO (HS CODE 382100) 103
5.6.2 EXPORT SCENARIO (HS CODE 382100) 104
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 105
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 106
5.9 INVESTMENT AND FUNDING SCENARIO 107
5.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 108
5.10 IMPACT OF 2025 US TARIFFS ON CELL CULTURE MARKET 109
5.10.1 INTRODUCTION 109
5.10.2 KEY TARIFF RATES 109
5.10.3 PRICE IMPACT ANALYSIS 110
5.10.4 IMPACT ON COUNTRY/REGION 111
5.10.4.1 US 111
5.10.4.2 Europe 111
5.10.4.3 Asia Pacific 112
5.10.5 IMPACT ON END-USE INDUSTRIES 112
5.10.5.1 Pharmaceutical & biotech companies 112
5.10.5.2 Hospitals & diagnostic laboratories 113
5.10.5.3 Academic & research institutes 113
5.10.5.4 Contract research organizations & contract development and manufacturing organizations 113
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 114
6.1 TECHNOLOGY ANALYSIS 114
6.1.1 KEY EMERGING TECHNOLOGIES 114
6.1.1.1 Single-use technology 114
6.1.1.2 Flow cytometry 116
6.1.1.3 Microscopy 116
6.1.2 COMPLEMENTARY TECHNOLOGIES 116
6.1.2.1 High-throughput screening 116
6.1.2.2 Mass spectrometry 116
6.1.3 ADJACENT TECHNOLOGIES 117
6.1.3.1 Microfluidics and organ-on-a-chip 117
6.1.3.2 3D bioprinting 117
6.2 TECHNOLOGY/PRODUCT ROADMAP 118
6.3 PATENT ANALYSIS 118
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL CULTURE PATENTS 119
6.4 FUTURE APPLICATIONS 121
6.5 IMPACT OF AI/GEN AI ON CELL CULTURE MARKET 122
6.5.1 BEST PRACTICES IN CELL CULTURE WORKFLOW 123
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL CULTURE MARKET 124
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 124
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL CULTURE MARKET 124
7 SUSTAINABILITY & REGULATORY LANDSCAPE 126
7.1 REGIONAL REGULATIONS & COMPLIANCE 126
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
7.1.2 REGULATORY FRAMEWORK 129
7.1.2.1 North America 129
7.1.2.2 Europe 129
7.1.2.3 Asia Pacific 130
7.1.2.4 Latin America 131
7.1.2.5 Middle East & Africa 131
7.1.3 INDUSTRY STANDARDS 131
 
7.2 SUSTAINABILITY INITIATIVES 132
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 132
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 133
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 134
8.1 DECISION-MAKING PROCESS 134
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 134
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 134
8.2.2 KEY BUYING CRITERIA, BY END USER 135
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 137
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 137
8.5 MARKET PROFITABILITY 137
9 CELL CULTURE MARKET, BY PRODUCT 138
9.1 INTRODUCTION 139
9.2 CONSUMABLES 139
9.2.1 SERA, MEDIA, AND REAGENTS 143
9.2.1.1 Media 147
9.2.1.1.1 Serum-free media 151
9.2.1.1.1.1 CHO media 156
9.2.1.1.1.1.1 High-yield biologics manufacturing to sustain demand for optimized CHO serum-free media 156
9.2.1.1.1.2 HEK 293 media 159
9.2.1.1.1.2.1 Viral vector manufacturing and transient expression workflows to accelerate HEK 293 media adoption 159
9.2.1.1.1.3 Serum-free stem cell media 163
9.2.1.1.1.3.1 Regenerative medicine, iPSC models, and cell therapy translation to drive specialized stem cell media demand 163
9.2.1.1.1.4 Vero Cell media 166
9.2.1.1.1.4.1 Increasing vaccine manufacturing to support demand for serum-free Vero cell media 166
9.2.1.1.1.5 BHK media 170
9.2.1.1.1.5.1 Vaccine production and viral vector workflows to support demand for BHK serum-free media 170
9.2.1.1.1.6 Other serum-free media 173
9.2.1.1.2 Classical media & salts 176
9.2.1.1.2.1 Standardized basal media and salt solutions to support routine culture, assay reproducibility, and vaccine production 176
9.2.1.1.3 Stem cell culture media 180
9.2.1.1.3.1 Rising use of stem cell models and regenerative medicine workflows to drive demand for specialized culture media 180
 
9.2.1.1.4 Chemically-defined media 183
9.2.1.1.4.1 Increasing need for reproducible, animal component-free workflows to support biologics and advanced therapy development 183
9.2.1.1.5 Specialty media 187
9.2.1.1.5.1 Suitability for use in selective cell types in bioprocessing and biomanufacturing industries to boost market 187
9.2.1.1.6 Other media 191
9.2.1.2 Reagents 195
9.2.1.2.1 Growth factors 199
9.2.1.2.1.1 Need to regulate cell proliferation, differentiation, and migration to sustain growth 199
9.2.1.2.2 Supplements 202
9.2.1.2.2.1 Need to improve cell growth, nutrient availability, and bioproduction performance to support segment growth 202
9.2.1.2.3 Buffers & chemicals 206
9.2.1.2.3.1 Ability to maintain stable pH levels to facilitate growth 206
9.2.1.2.4 Cell dissociation reagents 209
9.2.1.2.4.1 Ability to minimize cell stress and reduce cell damage to foster growth 209
9.2.1.2.5 Balanced salt solutions 213
9.2.1.2.5.1 Ability to maintain optimal physiological conditions for cell growth and experimentation to assist growth 213
9.2.1.2.6 Attachment & matrix factors 216
9.2.1.2.6.1 Rising adoption of 3D cell culture models to support growth 216
9.2.1.2.7 Antibiotics/Antimycotics 220
9.2.1.2.7.1 Ability to mitigate growth of contaminating bacteria, fungi, and mycoplasma to drive market 220
9.2.1.2.8 Cryoprotective reagents 223
9.2.1.2.8.1 Ability to preserve cell viability during freezing and thawing to aid growth 223
9.2.1.2.9 Contamination detection kits 226
9.2.1.2.9.1 Need for rapid identification of microbial contaminants to promote growth 226
9.2.1.2.10 Other reagents 230
9.2.1.3 Sera 233
9.2.1.3.1 Fetal bovine sera 236
9.2.1.3.1.1 Increasing role of fetal bovine sera in cell proliferation to favor growth 236
9.2.1.3.2 Adult bovine sera 240
9.2.1.3.2.1 Cost-effectiveness to contribute to growth 240
9.2.1.3.3 Other animal sera 243
 
9.2.2 VESSELS 247
9.2.2.1 Cell factory systems/cell stacks 250
9.2.2.1.1 Efficient and scalable solutions for large-scale expansion to drive adoption 250
9.2.2.2 Roller/roux bottles 254
9.2.2.2.1 Scalability, cost-effectiveness, and ease of handling to support growth 254
9.2.2.3 Flasks 257
9.2.2.3.1 Growing advancements in cell culture flasks to boost market 257
9.2.2.4 Multiwell plates 261
9.2.2.4.1 Increasing adoption of multiwell plates in high-throughput or high-content screening to aid growth 261
9.2.2.5 Petri dishes 264
9.2.2.5.1 Rising use of petri dishes as sterile containers to sustain growth 264
9.2.3 OTHER CONSUMABLES & ACCESSORIES 267
9.2.3.1 Reduced preparation time and equipment performance improvements to augment growth 267
9.3 EQUIPMENT 270
9.3.1 SUPPORTING EQUIPMENT 274
9.3.1.1 Filtration systems 277
9.3.1.1.1 Sterile filtration for contamination-controlled workflows to boost market 277
9.3.1.2 Cell counters 281
9.3.1.2.1 Growing adoption of automated cell counters to propel market 281
9.3.1.3 Carbon dioxide incubators 285
9.3.1.3.1 Increasing focus of research institutes on developing lab-scale incubators to drive market 285
9.3.1.4 Centrifuges 289
9.3.1.4.1 Increasing demand for bioproduction applications to drive adoption of centrifuges 289
9.3.1.5 Autoclaves 293
9.3.1.5.1 Reliance on single-use labware and equipment to affect demand for autoclaves 293
9.3.1.6 Microscopes 296
9.3.1.6.1 Rising adoption of live-cell imaging in 3D culture and stem cell models to support segment growth 296
9.3.1.7 Biosafety cabinets 300
9.3.1.7.1 Rising focus on contamination control and operator safety to support segment growth 300
9.3.1.8 Other supporting equipment 304
 
9.3.2 BIOREACTORS 307
9.3.2.1 Rising biologics and advanced therapy production to accelerate adoption of scalable bioreactor systems 307
9.3.3 STORAGE EQUIPMENT 311
9.3.3.1 Refrigerators & freezers 315
9.3.3.1.1 Increasing need for storage solutions to propel market 315
9.3.3.2 Cryostorage systems 318
9.3.3.2.1 Benefits of long-term preservation of cell cultures to support growth 318
10 CELL CULTURE MARKET, BY APPLICATION 322
10.1 INTRODUCTION 323
10.2 BIOPHARMACEUTICAL PRODUCTION 323
10.2.1 MONOCLONAL ANTIBODY PRODUCTION 327
10.2.1.1 Increasing approval and launch of monoclonal antibodies to amplify growth 327
10.2.2 VACCINE PRODUCTION 331
10.2.2.1 Rising incidence of infectious diseases to support growth 331
10.2.3 OTHER THERAPEUTIC PROTEIN PRODUCTION 335
10.3 DIAGNOSTICS 338
10.3.1 USE OF CULTURED CELLS IN CYTOGENETICS AND ASSAY VALIDATION TO SUPPORT SEGMENT GROWTH 338
10.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE 342
10.4.1 CELL & GENE THERAPY 346
10.4.1.1 Rising approvals and manufacturing investments in advanced therapies to propel segment growth 346
10.4.2 OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS 350
10.5 DRUG SCREENING & DEVELOPMENT 353
10.5.1 ADOPTION OF HUMAN-RELEVANT 3D MODELS AND AUTOMATED SCREENING PLATFORMS TO PROPEL SEGMENT GROWTH 353
10.6 OTHER APPLICATIONS 357
11 CELL CULTURE MARKET, BY END USER 360
11.1 INTRODUCTION 361
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 361
11.2.1 INCREASING DEMAND FOR CULTURE CELL LINES FOR DRUG SCREENING AND R&D TO AID GROWTH 361
11.3 HOSPITALS & DIAGNOSTIC LABORATORIES 365
11.3.1 GROWING USE OF CELL CULTURE FOR CELLULAR PHYSIOLOGY, DISEASE MECHANISMS, AND DRUG RESPONSES TO BOOST MARKET 365
11.4 ACADEMIC & RESEARCH INSTITUTES 369
11.4.1 RISING FUNDING ACTIVITIES TO CONTRIBUTE TO GROWTH 369
11.5 OTHER END USERS 372
 
12 CELL CULTURE MARKET, BY REGION 376
12.1 INTRODUCTION 377
12.2 NORTH AMERICA 377
12.2.1 US 385
12.2.1.1 Strong biologics pipeline and domestic cell therapy manufacturing investments to bolster growth 385
12.2.2 CANADA 392
12.2.2.1 Increasing funding and investments for cell-based therapies to boost market 392
12.3 EUROPE 399
12.3.1 GERMANY 406
12.3.1.1 Biologics manufacturing strength and mRNA oncology investments to drive demand 406
12.3.2 UK 412
12.3.2.1 ATMP clinical infrastructure and government life sciences strategy to boost growth 412
12.3.3 FRANCE 418
12.3.3.1 Rising number of cell-based research projects to enhance growth 418
12.3.4 ITALY 424
12.3.4.1 Strong government support for R&D activities to spur growth 424
12.3.5 SPAIN 430
12.3.5.1 Rising biotechnology R&D investment to support cell-based research applications 430
12.3.6 REST OF EUROPE 436
12.4 ASIA PACIFIC 442
12.4.1 CHINA 450
12.4.1.1 Large-scale CRDMO activity and multinational cell therapy investments to accelerate growth 450
12.4.2 JAPAN 457
12.4.2.1 Rising government initiatives and increasing investments in biotech to intensify growth 457
12.4.3 INDIA 463
12.4.3.1 Favorable government support and expansion by key cell culture players to augment growth 463
12.4.4 SOUTH KOREA 469
12.4.4.1 Growing pharmaceutical sector to drive market 469
12.4.5 AUSTRALIA 475
12.4.5.1 Regenerative medicine funding and hospital-linked CAR-T manufacturing to support growth 475
12.4.6 REST OF ASIA PACIFIC 481
 
12.5 LATIN AMERICA 488
12.5.1 BRAZIL 495
12.5.1.1 Cell therapy partnerships and vaccine manufacturing capacity to strengthen regional leadership 495
12.5.2 MEXICO 501
12.5.2.1 Pharmaceutical manufacturing investments and clinical research capacity to support steady growth 501
12.5.3 REST OF LATIN AMERICA 507
12.6 MIDDLE EAST 514
12.6.1 GCC COUNTRIES 521
12.6.1.1 Saudi Arabia 527
12.6.1.1.1 Increasing focus on expansion to drive market 527
12.6.1.2 UAE 533
12.6.1.2.1 Increasing shift from importing to manufacturing pharmaceuticals to boost market 533
12.6.1.3 Rest of GCC Countries 539
12.6.2 REST OF MIDDLE EAST 545
12.7 AFRICA 551
12.7.1 RISING GRANTS AND FUNDING FOR CELL AND GENE THERAPY PRODUCTS TO FOSTER GROWTH 551
13 COMPETITIVE LANDSCAPE 558
13.1 OVERVIEW 558
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 558
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL CULTURE MARKET 558
13.3 REVENUE ANALYSIS, 2021–2025 560
13.4 MARKET SHARE ANALYSIS, 2025 561
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 563
13.5.1 STARS 564
13.5.2 EMERGING LEADERS 564
13.5.3 PERVASIVE PLAYERS 564
13.5.4 PARTICIPANTS 564
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 566
13.5.5.1 Company footprint 566
13.5.5.2 Regional footprint 566
13.5.5.3 Product footprint 567
13.5.5.4 Application footprint 568
13.5.5.5 End-user footprint 569
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 570
13.6.1 PROGRESSIVE COMPANIES 570
13.6.2 RESPONSIVE COMPANIES 570
13.6.3 DYNAMIC COMPANIES 570
13.6.4 STARTING BLOCKS 570
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 571
13.6.5.1 Detailed list of key startups/SMEs 571
13.6.5.2 Competitive benchmarking of key startups/SMEs 572
13.7 COMPANY VALUATION AND FINANCIAL METRICS 573
13.7.1 FINANCIAL METRICS 573
13.7.2 COMPANY VALUATION 573
13.8 BRAND/PRODUCT COMPARISON 574
13.9 COMPETITIVE SCENARIO 574
13.9.1 PRODUCT LAUNCHES 574
13.9.2 DEALS 575
13.9.3 EXPANSIONS 576
14 COMPANY PROFILES 578
14.1 INTRODUCTION 578
14.2 KEY PLAYERS 578
14.2.1 THERMO FISHER SCIENTIFIC INC. 578
14.2.1.1 Business overview 578
14.2.1.2 Products offered 579
14.2.1.3 Recent developments 592
14.2.1.3.1 Product launches 592
14.2.1.3.2 Deals 594
14.2.1.3.3 Expansions 595
14.2.1.4 MnM view 596
14.2.1.4.1 Right to win 596
14.2.1.4.2 Strategic choices 596
14.2.1.4.3 Weaknesses and competitive threats 596
14.2.2 DANAHER CORPORATION 597
14.2.2.1 Business overview 597
14.2.2.2 Products offered 598
14.2.2.3 Recent developments 608
14.2.2.3.1 Product launches 608
14.2.2.3.2 Deals 609
14.2.2.3.3 Expansions 610
14.2.2.3.4 Other developments 611
14.2.2.4 MnM view 611
14.2.2.4.1 Right to win 611
14.2.2.4.2 Strategic choices 612
14.2.2.4.3 Weaknesses and competitive threats 612
 
14.2.3 MERCK KGAA 613
14.2.3.1 Business overview 613
14.2.3.2 Products offered 614
14.2.3.3 Recent developments 621
14.2.3.3.1 Product launches 621
14.2.3.3.2 Deals 621
14.2.3.3.3 Expansions 622
14.2.3.4 MnM view 624
14.2.3.4.1 Right to win 624
14.2.3.4.2 Strategic choices 624
14.2.3.4.3 Weaknesses and competitive threats 624
14.2.4 SARTORIUS AG 625
14.2.4.1 Business overview 625
14.2.4.2 Products offered 626
14.2.4.3 Recent developments 634
14.2.4.3.1 Product launches 634
14.2.4.3.2 Deals 635
14.2.4.3.3 Expansions 637
14.2.4.4 MnM view 638
14.2.4.4.1 Right to win 638
14.2.4.4.2 Strategic choices 638
14.2.4.4.3 Weaknesses and competitive threats 639
14.2.5 CORNING INCORPORATED 640
14.2.5.1 Business overview 640
14.2.5.2 Products offered 641
14.2.5.3 Recent developments 650
14.2.5.3.1 Deals 650
14.2.6 FUJIFILM HOLDINGS CORPORATION 652
14.2.6.1 Business overview 652
14.2.6.2 Products offered 653
14.2.6.3 Recent developments 659
14.2.6.3.1 Product launches 659
14.2.6.3.2 Deals 660
14.2.6.3.3 Other developments 660
14.2.7 BD 661
14.2.7.1 Business overview 661
14.2.7.2 Product offered 662
14.2.7.3 Recent developments 664
14.2.7.3.1 Product Launches 664
14.2.7.3.2 Deals 664
14.2.7.3.3 Other developments 665
 
14.2.8 EPPENDORF SE 666
14.2.8.1 Business overview 666
14.2.8.2 Products offered 667
14.2.8.3 Recent developments 672
14.2.8.3.1 Product launches 672
14.2.8.3.2 Expansions 673
14.2.9 LONZA 674
14.2.9.1 Business overview 674
14.2.9.2 Products offered 675
14.2.9.3 Recent developments 678
14.2.9.3.1 Product launches 678
14.2.9.3.2 Deals 678
14.2.10 GETINGE 679
14.2.10.1 Business overview 679
14.2.10.2 Products offered 680
14.2.10.3 Recent developments 681
14.2.10.3.1 Product launches 681
14.2.10.3.2 Deals 682
14.2.11 AGILENT TECHNOLOGIES, INC. 683
14.2.11.1 Business overview 683
14.2.11.2 Products offered 684
14.2.11.3 Recent developments 686
14.2.11.3.1 Product launches 686
14.2.11.3.2 Deals 687
14.2.11.3.3 Expansions 687
14.2.12 HIMEDIA LABORATORIES 688
14.2.12.1 Business overview 688
14.2.12.2 Products offered 688
14.2.13 BIO-TECHNE 692
14.2.13.1 Business overview 692
14.2.13.2 Products offered 693
14.2.13.3 Recent developments 697
14.2.13.3.1 Product launches 697
14.2.13.3.2 Deals 697
14.2.13.3.3 Expansions 698
14.3 OTHER PLAYERS 699
14.3.1 MILTENYI BIOTEC 699
14.3.2 STEMCELL TECHNOLOGIES 701
14.3.3 SOLIDA BIOTECH GMBH 704
14.3.4 CAISSON LABS 705
14.3.5 PROMOCELL GMBH 706
14.3.6 INVIVOGEN 707
14.3.7 PAN-BIOTECH 708
14.3.8 CELLEXUS 709
14.3.9 MEISSNER FILTRATION PRODUCTS, INC. 710
14.3.10 ADOLF KÜHNER AG 712
14.3.11 ADVANCION CORPORATION 713
14.3.12 BIOSPHERIX LLC 714
15 RESEARCH METHODOLOGY 715
15.1 RESEARCH DATA 715
15.1.1 SECONDARY DATA 716
15.1.1.1 Key secondary sources 716
15.1.1.2 Key data from secondary research 716
15.1.2 PRIMARY DATA 717
15.1.2.1 Key primary participants 717
15.1.2.2 Breakdown of primary interviews 717
15.1.2.3 Key data from primary sources 717
15.2 MARKET SIZE ESTIMATION 718
15.2.1 GLOBAL CELL CULTURE MARKET ESTIMATION, 2025 718
15.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up) 718
15.2.1.2 Approach 2: Primary research 720
15.2.1.2.1 Key industry insights 720
15.2.1.3 Approach 3: MnM repository analysis 720
15.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 721
15.3 MARKET GROWTH RATE PROJECTIONS 722
15.4 DATA TRIANGULATION 724
15.5 RESEARCH ASSUMPTIONS 725
15.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT 726
16 APPENDIX 727
16.1 DISCUSSION GUIDE 727
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 731
16.3 CUSTOMIZATION OPTIONS 733
16.4 RELATED REPORTS 733
16.5 AUTHOR DETAILS 735

ページTOPに戻る

List of Tables/Graphs

TABLE 1 CELL CULTURE MARKET: INCLUSIONS AND EXCLUSIONS 61
TABLE 2 CELL CULTURE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 76
TABLE 3 NATIONAL INSTITUTES OF HEALTH FUNDING FOR STEM CELL-BASED RESEARCH, 2020–2024 (USD MILLION) 77
TABLE 4 FUNDING INVESTMENTS IN CELL & GENE THERAPY, 2023–2026 77
TABLE 5 COMMERCIALLY SPONSORED MONOCLONAL ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN 2025 79
TABLE 6 ASIA PACIFIC: PRIVATE ROUNDS IN BIOTECH COMPANIES FOCUSED ON HEALTHCARE, 2024–2026 86
TABLE 7 COMPARISON OF SINGLE-USE BIOPROCESSING SYSTEM DISPOSAL OPTIONS 89
TABLE 8 CELL CULTURE MARKET: IMPACT OF PORTER’S FIVE FORCES 92
TABLE 9 CELL CULTURE MARKET: ROLE IN ECOSYSTEM 98
TABLE 10 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT,
2023–2025 (USD) 99
TABLE 11 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS, BY REGION, 2023–2025 (USD) 101
TABLE 12 IMPORT DATA FOR HS CODE 382100, 2021–2025 (USD THOUSAND) 103
TABLE 13 IMPORT DATA FOR HS CODE 382100, 2021–2025 (TONS) 103
TABLE 14 EXPORT DATA FOR HS CODE 382100, 2021–2025 (USD THOUSAND) 104
TABLE 15 EXPORT DATA FOR HS CODE 382100, 2021–2025 (TONS) 105
TABLE 16 CELL CULTURE MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 105
TABLE 17 US ADJUSTED RECIPROCAL TARIFF RATES 109
TABLE 18 IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS 112
TABLE 19 ADVANTAGES OF SINGLE-USE OVER STAINLESS-STEEL BIOREACTORS 115
TABLE 20 ADVANTAGES AND DISADVANTAGES OF MICROFLUIDIC CELL CULTURE 117
TABLE 21 CELL CULTURE MARKET: INDICATIVE LIST OF PATENTS, 2026 120
TABLE 22 CASE STUDIES OF AI IMPLEMENTATION IN CELL CULTURE MARKET 124
TABLE 23 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN CELL CULTURE 125
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 27 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 135
TABLE 29 KEY BUYING CRITERIA, BY END USER 136
TABLE 30 CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 139
TABLE 31 CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 32 CELL CULTURE CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 33 NORTH AMERICA: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 34 EUROPE: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 35 ASIA PACIFIC: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 36 LATIN AMERICA: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 37 MIDDLE EAST: CELL CULTURE CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 142
TABLE 38 GCC COUNTRIES: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 39 CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 143
TABLE 40 CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 41 NORTH AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 42 EUROPE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 43 ASIA PACIFIC: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 44 LATIN AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 45 MIDDLE EAST: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 46 GCC COUNTRIES: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 47 CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 147
TABLE 48 CELL CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 49 NORTH AMERICA: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 50 EUROPE: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 51 ASIA PACIFIC: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 52 LATIN AMERICA: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 53 MIDDLE EAST: CELL CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 54 GCC COUNTRIES: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 55 CELL CULTURE MEDIA MARKET, BY REGION, 2024–2031 (MILLION LITERS) 151
TABLE 56 SERUM-FREE MEDIA OFFERED BY KEY MARKET PLAYERS 152
TABLE 57 CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 152
TABLE 58 CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 59 NORTH AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 60 EUROPE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 61 ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 62 LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 63 MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 64 GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 65 CELL CULTURE MARKET FOR CHO MEDIA, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 66 NORTH AMERICA: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 67 EUROPE: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 68 ASIA PACIFIC: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 69 LATIN AMERICA: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 70 MIDDLE EAST: CELL CULTURE MARKET FOR CHO MEDIA, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 71 GCC COUNTRIES: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 72 CELL CULTURE MARKET FOR HEK 293 MEDIA, BY REGION,
2024–2031 (USD MILLION) 160
TABLE 73 NORTH AMERICA: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 74 EUROPE: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 75 ASIA PACIFIC: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 76 LATIN AMERICA: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 77 MIDDLE EAST: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 78 GCC COUNTRIES: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 79 CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 80 NORTH AMERICA: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 81 EUROPE: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 82 ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 83 LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 84 MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY REGION, 2024–2031 (USD MILLION) 165
TABLE 85 GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 86 CELL CULTURE MARKET FOR VERO CELL MEDIA, BY REGION,
2024–2031 (USD MILLION) 167
TABLE 87 NORTH AMERICA: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 88 EUROPE: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 89 ASIA PACIFIC: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 90 LATIN AMERICA: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 91 MIDDLE EAST: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 92 GCC COUNTRIES: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 93 CELL CULTURE MARKET FOR BHK MEDIA, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 94 NORTH AMERICA: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 95 EUROPE: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 96 ASIA PACIFIC: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 97 LATIN AMERICA: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 98 MIDDLE EAST: CELL CULTURE MARKET FOR BHK MEDIA, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 99 GCC COUNTRIES: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 100 CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 101 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 102 EUROPE: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 103 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 104 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 105 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY REGION, 2024–2031 (USD MILLION) 175
TABLE 106 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 107 CLASSICAL MEDIA & SALTS OFFERED BY KEY MARKET PLAYERS 176
TABLE 108 CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 109 NORTH AMERICA: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 110 EUROPE: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 111 ASIA PACIFIC: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 112 LATIN AMERICA: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 113 MIDDLE EAST: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY REGION, 2024–2031 (USD MILLION) 179
TABLE 114 GCC COUNTRIES: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 115 STEM CELL CULTURE MEDIA OFFERED BY KEY MARKET PLAYERS 180
TABLE 116 CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 117 NORTH AMERICA: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 118 EUROPE: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 119 ASIA PACIFIC: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 120 LATIN AMERICA: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 121 MIDDLE EAST: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY REGION, 2024–2031 (USD MILLION) 182
TABLE 122 GCC COUNTRIES: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 123 CHEMICALLY-DEFINED MEDIA OFFERED BY KEY MARKET PLAYERS 184
TABLE 124 CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA, BY REGION,
2024–2031 (USD MILLION) 184
TABLE 125 NORTH AMERICA: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 126 EUROPE: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 127 ASIA PACIFIC: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 128 LATIN AMERICA: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 129 MIDDLE EAST: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY REGION, 2024–2031 (USD MILLION) 186
TABLE 130 GCC COUNTRIES: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 131 SPECIALTY MEDIA OFFERED BY KEY MARKET PLAYERS 187
TABLE 132 CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY REGION,
2024–2031 (USD MILLION) 188
TABLE 133 NORTH AMERICA: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 134 EUROPE: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 135 ASIA PACIFIC: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 136 LATIN AMERICA: CELL CULTURE MARKET FOR SPECIALTY ME
DIA, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 137 MIDDLE EAST: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 138 GCC COUNTRIES: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 139 OTHER MEDIA OFFERED BY KEY MARKET PLAYERS 191
TABLE 140 CELL CULTURE MARKET FOR OTHER MEDIA, BY REGION,
2024–2031 (USD MILLION) 192
TABLE 141 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 142 EUROPE: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 143 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 144 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 145 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER MEDIA, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 146 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 147 CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 148 CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 149 NORTH AMERICA: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 150 EUROPE: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 151 ASIA PACIFIC: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 152 LATIN AMERICA: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 153 MIDDLE EAST: CELL CULTURE REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 198
TABLE 154 GCC COUNTRIES: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 155 CELL CULTURE MARKET FOR GROWTH FACTORS, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 156 NORTH AMERICA: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 157 EUROPE: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 158 ASIA PACIFIC: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 159 LATIN AMERICA: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 160 MIDDLE EAST: CELL CULTURE MARKET FOR GROWTH FACTORS, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 161 GCC COUNTRIES: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 162 CELL CULTURE MARKET FOR SUPPLEMENTS, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 163 NORTH AMERICA: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 164 EUROPE: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 165 ASIA PACIFIC: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 166 LATIN AMERICA: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 167 MIDDLE EAST: CELL CULTURE MARKET FOR SUPPLEMENTS, BY REGION,
2024–2031 (USD MILLION) 205
TABLE 168 GCC COUNTRIES: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 169 CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY REGION,
2024–2031 (USD MILLION) 206
TABLE 170 NORTH AMERICA: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 171 EUROPE: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 172 ASIA PACIFIC: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 173 LATIN AMERICA: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 174 MIDDLE EAST: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY REGION, 2024–2031 (USD MILLION) 208
TABLE 175 GCC COUNTRIES: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 176 CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 177 NORTH AMERICA: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 178 EUROPE: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 179 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 180 LATIN AMERICA: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 181 MIDDLE EAST: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 182 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 183 CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 184 NORTH AMERICA: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 185 EUROPE: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 186 ASIA PACIFIC: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 187 LATIN AMERICA: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 188 MIDDLE EAST: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY REGION, 2024–2031 (USD MILLION) 215
TABLE 189 GCC COUNTRIES: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 190 CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY REGION, 2024–2031 (USD MILLION) 217
TABLE 191 NORTH AMERICA: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 192 EUROPE: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 193 ASIA PACIFIC: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 194 LATIN AMERICA: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 195 MIDDLE EAST: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY REGION, 2024–2031 (USD MILLION) 219
TABLE 196 GCC COUNTRIES: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 197 CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS, BY REGION,
2024–2031 (USD MILLION) 220
TABLE 198 NORTH AMERICA: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 199 EUROPE: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 200 ASIA PACIFIC: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 201 LATIN AMERICA: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 202 MIDDLE EAST: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY REGION, 2024–2031 (USD MILLION) 222
TABLE 203 GCC COUNTRIES: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 204 CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS, BY REGION,
2024–2031 (USD MILLION) 223
TABLE 205 NORTH AMERICA: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 206 EUROPE: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 207 ASIA PACIFIC: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 208 LATIN AMERICA: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 209 MIDDLE EAST: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 225
TABLE 210 GCC COUNTRIES: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 211 CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 212 NORTH AMERICA: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 213 EUROPE: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 214 ASIA PACIFIC: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 215 LATIN AMERICA: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 216 MIDDLE EAST: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY REGION, 2024–2031 (USD MILLION) 229
TABLE 217 GCC COUNTRIES: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 218 CELL CULTURE MARKET FOR OTHER REAGENTS, BY REGION,
2024–2031 (USD MILLION) 230
TABLE 219 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 220 EUROPE: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 221 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 222 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 223 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER REAGENTS, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 224 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 225 CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 226 CELL CULTURE SERA MARKET, BY REGION, 2024–2031 (USD MILLION) 234
TABLE 227 NORTH AMERICA: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 228 EUROPE: CELL CULTURE SERA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 229 ASIA PACIFIC: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 230 LATIN AMERICA: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 231 MIDDLE EAST: CELL CULTURE SERA MARKET, BY REGION,
2024–2031 (USD MILLION) 236
TABLE 232 GCC COUNTRIES: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 236
TABLE 233 CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 234 NORTH AMERICA: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 235 EUROPE: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 236 ASIA PACIFIC: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 237 LATIN AMERICA: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 238 MIDDLE EAST: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 239 GCC COUNTRIES: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 240 CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY REGION,
2024–2031 (USD MILLION) 240
TABLE 241 NORTH AMERICA: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 242 EUROPE: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY,
2024–2031 (USD MILLION) 241
TABLE 243 ASIA PACIFIC: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 244 LATIN AMERICA: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 245 MIDDLE EAST: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY REGION, 2024–2031 (USD MILLION) 242
TABLE 246 GCC COUNTRIES: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 247 CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 248 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER ANIMAL SERA,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 249 EUROPE: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY,
2024–2031 (USD MILLION) 245
TABLE 250 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 251 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 252 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY REGION, 2024–2031 (USD MILLION) 246
TABLE 253 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER ANIMAL SERA,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 254 CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 255 CELL CULTURE VESSELS MARKET, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 256 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 248
TABLE 257 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 248
TABLE 258 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 249
TABLE 259 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 249
TABLE 260 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION,
2024–2031 (USD MILLION) 249
TABLE 261 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 262 CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY REGION, 2024–2031 (USD MILLION) 251
TABLE 263 NORTH AMERICA: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 264 EUROPE: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 265 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 266 LATIN AMERICA: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 267 MIDDLE EAST: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 268 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 269 CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY REGION,
2024–2031 (USD MILLION) 254
TABLE 270 NORTH AMERICA: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 271 EUROPE: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 272 ASIA PACIFIC: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 273 LATIN AMERICA: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 274 MIDDLE EAST: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY REGION, 2024–2031 (USD MILLION) 256
TABLE 275 GCC COUNTRIES: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 276 CELL CULTURE MARKET FOR FLASKS, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 277 NORTH AMERICA: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 278 EUROPE: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 279 ASIA PACIFIC: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 280 LATIN AMERICA: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 281 MIDDLE EAST: CELL CULTURE MARKET FOR FLASKS, BY REGION,
2024–2031 (USD MILLION) 260
TABLE 282 GCC COUNTRIES: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 283 CELL CULTURE MARKET FOR MULTIWELL PLATES, BY REGION,
2024–2031 (USD MILLION) 261
TABLE 284 NORTH AMERICA: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 285 EUROPE: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY,
2024–2031 (USD MILLION) 262
TABLE 286 ASIA PACIFIC: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 287 LATIN AMERICA: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 288 MIDDLE EAST: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY REGION, 2024–2031 (USD MILLION) 263
TABLE 289 GCC COUNTRIES: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 290 CELL CULTURE MARKET FOR PETRI DISHES, BY REGION,
2024–2031 (USD MILLION) 264
TABLE 291 NORTH AMERICA: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 292 EUROPE: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 265
TABLE 293 ASIA PACIFIC: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 294 LATIN AMERICA: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 295 MIDDLE EAST: CELL CULTURE MARKET FOR PETRI DISHES, BY REGION,
2024–2031 (USD MILLION) 266
TABLE 296 GCC COUNTRIES: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 297 CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 298 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 299 EUROPE: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 300 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 301 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 302 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 303 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 304 CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 305 CELL CULTURE EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 271
TABLE 306 NORTH AMERICA: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 307 EUROPE: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 308 ASIA PACIFIC: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 309 LATIN AMERICA: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 310 MIDDLE EAST: CELL CULTURE EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 273
TABLE 311 GCC COUNTRIES: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 312 CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 274
TABLE 313 CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY REGION,
2024–2031 (USD MILLION) 274
TABLE 314 NORTH AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 315 EUROPE: CELL CULTURE MARKET FOR